Table 3.

Models of longitudinal prediction of maternal serum homocysteine and vitamin B-12 and milk B-12 trajectories based on the presence of anxiety symptoms at the 3^rd trimester of pregnancy, Rio de Janeiro, Brazil.

Unadjusted model	Log serum homocysteine (mg/ L) (n = 90)		Log serum B-12 (pmol/L) (n = 90)		Log milk B-12 (pmol/L) (n = 94)
	β (SE)a	P	β (SE) a	P	β (SE) a	P
Main effects
With vs. without anxiety symptoms at 3rd trimesterb	0.141 (0.060)	0.021	−0.182 (0.001)	0.082	−0.251 (0.177)	0.160
Postpartum days	−0.001 (0.001)	0.313	0.000 (0.001)	0.029	−0.004 (0.002)	0.081
Interaction term Postpartum days # with vs. without anxiety symptoms at 3rd trimester	−0.002 (0.001)	0.035	0.000 (0.000)	0.895	0.001 (0.003)	0.876
Adjusted model	β (SE)a	P c	β (SE) a	P c	β (SE) a	P d
Main effects
With vs. without anxiety symptoms at 3rd trimesterb	0.167 (0.064)	0.010	−0.179 (0.109)	0.104	−0.168 (0.181)	0.354
Postpartum days	−0.001 (0.001)	0.348	0.002 (0.001)	0.019	−0.004 (0.002)	0.092
Interaction term Postpartum days # with vs. without anxiety symptoms at 3rd trimester	−0.002 (0.001)	0.024	−0.000 (0.001)	0.797	0.002 (0.004)	0.585

^aLongitudinal mixed-effect model with beta coefficients (β) and standard error (SE), p-value refers to maximum likelihood estimator.

^bAnxiety state was assessed by the State-Trait Anxiety Inventory (STAI), yes (STAI ≥40) and no (STAI <40).

^cModels were adjusted for maternal age, education, pre-pregnancy BMI, B-vitamin (including folate) supplement intake during pregnancy, and serum folate concentration at the 3rd trimester of pregnancy.

^dModel was adjusted for pre-pregnancy BMI, B-vitamin (including folate) supplement intake during pregnancy, and serum B-12 concentration at the 3rd trimester of pregnancy. # refers to the interaction term.